Last reviewed · How we verify
Zoledronic acid 5mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Zoledronic acid 5mg (Zoledronic acid 5mg) — Novartis Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Zoledronic acid 5mg TARGET | Zoledronic acid 5mg | Novartis Pharmaceuticals | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Zoledronic acid 5mg CI watch — RSS
- Zoledronic acid 5mg CI watch — Atom
- Zoledronic acid 5mg CI watch — JSON
- Zoledronic acid 5mg alone — RSS
Cite this brief
Drug Landscape (2026). Zoledronic acid 5mg — Competitive Intelligence Brief. https://druglandscape.com/ci/zoledronic-acid-5mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing